Dual-Target CAR-T therapy offers new hope for Hard-to-Treat myeloma
NCT ID NCT07359014
Summary
This study is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this therapy can control the cancer and to check for side effects. About 25 participants will be enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuzhao Zhang
RECRUITINGHangzhou, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.